IVVD vs KLRS

Invivyd, Inc. vs Kalaris Therapeutics, Inc. — Valuation Comparison 2026

IVVD

Biological Products, (No Diagnostic Substances)
Invivyd, Inc.
Quality
4.3
out of 10
Value Trap
24
SAFE
Price
$1.14
Last close
Models
4/13
Active
VS

KLRS

Biological Products, (No Diagnostic Substances)
Kalaris Therapeutics, Inc.
Quality
4.1
out of 10
Value Trap
30
LOW
Price
$5.27
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType IVVD Fair ValueIVVD Upside KLRS Fair ValueKLRS Upside
Bayesian DCF Intrinsic $0.38 -92.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.23 -84.6% $1.17 -77.7%
PWERM Option-Based $0.21 -82.0% $4.16 -21.0%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for IVVD vs KLRS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

IVVD vs KLRS — Which Stock Is More Undervalued?

IVVD scores higher with a 4.3/10 quality rating vs KLRS's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Invivyd, Inc. (IVVD) and Kalaris Therapeutics, Inc. (KLRS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

IVVD currently trades at $1.14 with a QOC of 4.3/10, while KLRS trades at $5.27 with a QOC of 4.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).